cefditoren pivoxil (BioDeep_00000177111)

   

human metabolite blood metabolite


代谢物信息卡片


{7-[2-(2-imino-2,3-dihydro-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carbonyloxy}methyl 2,2-dimethylpropanoic acid

化学式: C25H28N6O7S3 (620.1181538)
中文名称:
谱图信息: 最多检出来源 Homo sapiens(blood) 50%

分子结构信息

SMILES: CON=C(C(=O)NC1C2SCC(C=CC3=C(C)N=CS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)C1=CSC(N)=N1
InChI: InChI=1S/C25H28N6O7S3/c1-12-15(41-10-27-12)7-6-13-8-39-21-17(29-19(32)16(30-36-5)14-9-40-24(26)28-14)20(33)31(21)18(13)22(34)37-11-38-23(35)25(2,3)4/h6-7,9-10,17,21H,8,11H2,1-5H3,(H2,26,28)(H,29,32)

描述信息

同义名列表

3 个代谢物同义名

{7-[2-(2-imino-2,3-dihydro-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carbonyloxy}methyl 2,2-dimethylpropanoic acid; {7-[2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carbonyloxy}methyl 2,2-dimethylpropanoate; cefditoren pivoxil



数据库引用编号

2 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Masanori Ito, Mitsumasa Fukuda, Yuka Suzuki, Hiroyuki Wakamoto, Eiichi Ishii. Carnitine-related hypoglycemia caused by 3 days of pivalate antibiotic therapy in a patient with severe muscular dystrophy: a case report. BMC pediatrics. 2017 03; 17(1):73. doi: 10.1186/s12887-017-0835-7. [PMID: 28292283]
  • Nawal A Alarfaj, Fatma A Aly, Maha F El-Tohamy. Application of silver nanoparticles to the chemiluminescence determination of cefditoren pivoxil using the luminol-ferricyanide system. Luminescence : the journal of biological and chemical luminescence. 2015 Feb; 30(1):91-7. doi: 10.1002/bio.2696. [PMID: 24850667]
  • Gojjala Venugopalarao, Rajasekhar Lakshmipathy, Nallani Chakravarthula Sarada. Preparation and characterization of cefditoren pivoxil-loaded liposomes for controlled in vitro and in vivo drug release. International journal of nanomedicine. 2015; 10 Suppl 1(?):149-57. doi: 10.2147/ijn.s79994. [PMID: 26491316]
  • Kayoko Matsumoto, Nobuo Sato, Nayu Mitomi, Shigeki Shibasaki. Population pharmacokinetic analysis of cefditoren pivoxil in pediatric patients with infection. The Japanese journal of antibiotics. 2013 Dec; 66(6):357-75. doi: NULL. [PMID: 24649799]
  • Teerapong Monmaturapoj, Preecha Montakantikul, Piroon Mootsikapun, Pramote Tragulpiankit. A prospective, randomized, double dummy, placebo-controlled trial of oral cefditoren pivoxil 400mg once daily as switch therapy after intravenous ceftriaxone in the treatment of acute pyelonephritis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2012 Dec; 16(12):e843-9. doi: 10.1016/j.ijid.2012.07.009. [PMID: 22951426]
  • Eric P Brass, Michael D Mayer, Darcy J Mulford, Therese K Stickler, Charles L Hoppel. Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil. Clinical pharmacology and therapeutics. 2003 Apr; 73(4):338-47. doi: 10.1016/s0009-9236(02)17636-3. [PMID: 12709724]
  • Malcolm J M Darkes, Greg L Plosker. Cefditoren pivoxil. Drugs. 2002; 62(2):319-36; discussion 337. doi: 10.2165/00003495-200262020-00006. [PMID: 11817976]
  • J T Li, F Hou, H Lu, T Y Li, H Li. Phase I clinical trial of cefditoren pivoxil (ME 1207): pharmacokinetics in healthy volunteers. Drugs under experimental and clinical research. 1997; 23(5-6):145-50. doi: NULL. [PMID: 9515223]
  • T Motohiro, S Handa, S Yamada, S Oki, Y Yoshinaga, H Sasaki, M Aramaki, K Oda, Y Sakata, H Kato. [Basic and clinical studies on cefditoren pivoxil in pediatric field]. The Japanese journal of antibiotics. 1994 Apr; 47(4):409-27. doi: NULL. [PMID: 8201769]
  • N Iwai, H Nakamura, M Miyazu, Y Watanabe. [Pharmacokinetic, bacteriological and clinical evaluation of cefditoren pivoxil in pediatrics]. The Japanese journal of antibiotics. 1994 Feb; 47(2):181-94. doi: NULL. [PMID: 8151911]
  • R Fujii, S Chiba, K Numazaki, T Mori, I Terashima, H Meguro, A Mori, Y Toyonaga, K Sunakawa, Y Satoh. [Effect of cefditoren pivoxil on carnitine metabolism in pediatric patients]. The Japanese journal of antibiotics. 1993 Oct; 46(10):926-37. doi: NULL. [PMID: 8254895]
  • Y Toyonaga, T Ishihara, T Sano, T Tezuka, H Nakamura. [Bacteriological, pharmacokinetic and clinical studies of cefditoren pivoxil in the pediatric field]. The Japanese journal of antibiotics. 1993 Jul; 46(7):604-28. doi: . [PMID: 8371496]
  • T Tajima, M Kobayashi, S Negishi, S Nishimura, A Yoshida, S Kudo, M Gondou, T Nakayama, T Abe. [Pharmacokinetic, bacteriological and clinical studies on cefditoren pivoxil in children]. The Japanese journal of antibiotics. 1993 Jul; 46(7):589-95. doi: NULL. [PMID: 8371494]
  • S Arakawa, S Takagi, S Kamidono, N Kataoka, O Tomioka, M Hazama, T Hirose, K Yamazaki, Y Kumamoto, K Hayashi. [Clinical long-term studies of the treatment of chronic complicated urinary tract infections. Utility and recurrence after 14-day treatment by cefditoren pivoxil]. The Japanese journal of antibiotics. 1993 Jan; 46(1):75-94. doi: NULL. [PMID: 8455334]